Crossmark Global Holdings’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.82M | Buy |
8,597
+93
| +1% | +$18.3K | 0.02% | 478 |
|
|
2026
Q1 | $1.67M | Buy |
8,504
+1
| +0% | +$194 | 0.02% | 477 |
|
|
2025
Q4 | $1.48M | Buy |
8,503
+2,956
| +53% | +$538K | 0.02% | 500 |
|
|
2025
Q3 | $1.06M | Sell |
5,547
-177
| -3% | -$31.4K | 0.02% | 608 |
|
|
2025
Q2 | $1.03M | Sell |
5,724
-603
| -10% | -$105K | 0.02% | 599 |
|
|
2025
Q1 | $1.07M | Sell |
6,327
-17
| -0.3% | -$2.79K | 0.02% | 590 |
|
|
2024
Q4 | $957K | Sell |
6,344
-303
| -5% | -$47.1K | 0.02% | 595 |
|
|
2024
Q3 | $1.03M | Sell |
6,647
-2,610
| -28% | -$390K | 0.02% | 598 |
|
|
2024
Q2 | $1.27M | Buy |
9,257
+2,084
| +29% | +$285K | 0.02% | 515 |
|
|
2024
Q1 | $955K | Sell |
7,173
-4,149
| -37% | -$538K | 0.02% | 629 |
|
|
2023
Q4 | $1.56M | Sell |
11,322
-97,680
| -90% | -$12.8M | 0.03% | 471 |
|
|
2023
Q3 | $13.5M | Buy |
109,002
+244
| +0.2% | +$32.5K | 0.31% | 80 |
|
|
2023
Q2 | $14.6M | Sell |
108,758
-8,634
| -7% | -$1.19M | 0.31% | 74 |
|
|
2023
Q1 | $16.6M | Sell |
117,392
-1,978
| -2% | -$283K | 0.39% | 56 |
|
|
2022
Q4 | $18.7M | Buy |
119,370
+416
| +0.3% | +$59.8K | 0.47% | 39 |
|
|
2022
Q3 | $14.6M | Buy |
118,954
+591
| +0.5% | +$77.8K | 0.4% | 51 |
|
|
2022
Q2 | $15.7M | Buy |
118,363
+530
| +0.4% | +$72.2K | 0.41% | 47 |
|
|
2022
Q1 | $16.1M | Buy |
117,833
+1,679
| +1% | +$234K | 0.36% | 59 |
|
|
2021
Q4 | $20.1M | Buy |
116,154
+8,782
| +8% | +$1.34M | 0.44% | 41 |
|
|
2021
Q3 | $15.6M | Buy |
107,372
+1,246
| +1% | +$182K | 0.37% | 58 |
|
|
2021
Q2 | $14M | Buy |
106,126
+5,031
| +5% | +$659K | 0.33% | 67 |
|
|
2021
Q1 | $13M | Sell |
101,095
-5,492
| -5% | -$677K | 0.32% | 72 |
|
|
2020
Q4 | $12.7M | Sell |
106,587
-5,621
| -5% | -$685K | 0.32% | 71 |
|
|
2020
Q3 | $12.8M | Sell |
112,208
-5,250
| -4% | -$620K | 0.36% | 55 |
|
|
2020
Q2 | $13.4M | Sell |
117,458
-6,120
| -5% | -$649K | 0.39% | 51 |
|
|
2020
Q1 | $9.92M | Sell |
123,578
-1,640
| -1% | -$170K | 0.36% | 68 |
|
|
2019
Q4 | $13.4M | Buy |
125,218
+3,454
| +3% | +$360K | 0.37% | 67 |
|
|
2019
Q3 | $13M | Sell |
121,764
-2,819
| -2% | -$289K | 0.38% | 58 |
|
|
2019
Q2 | $12.7M | Sell |
124,583
-490
| -0.4% | -$47.1K | 0.36% | 60 |
|
|
2019
Q1 | $11.2M | Buy |
125,073
+772
| +0.6% | +$66.9K | 0.32% | 70 |
|
|
2018
Q4 | $10.4M | Sell |
124,301
-1,661
| -1% | -$156K | 0.32% | 70 |
|
|
2018
Q3 | $13.6M | Buy |
125,962
+3,365
| +3% | +$369K | 0.35% | 59 |
|
|
2018
Q2 | $13.5M | Buy |
122,597
+4,434
| +4% | +$462K | 0.36% | 51 |
|
|
2018
Q1 | $11.9M | Sell |
118,163
-2,163
| -2% | -$222K | 0.31% | 64 |
|
|
2017
Q4 | $11.9M | Buy |
120,326
+1,497
| +1% | +$142K | 0.28% | 75 |
|
|
2017
Q3 | $11.1M | Buy |
+118,829
| New | +$12.6M | 0.29% | 76 |
|
|
2016
Q3 | $11.1M | Buy |
+118,829
| New | +$9.98M | 0.29% | 76 |
|
Other funds holding DGX
EIG
Crossmark Global Holdings's DGX Position: Q2 2026 in Review
Crossmark Global Holdings increased its Quest Diagnostics (DGX) stake by 1.1% in Q2 2026, buying an estimated $18.3K and bringing the position to 8,597 shares worth $1.82M. The position accounts for 0.02% of the portfolio, ranked #478.
Crossmark Global Holdings first reported a position in DGX in Q3 2016 and has held it in 37 quarters since. The position peaked at $20.1M in Q4 2021. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Crossmark Global Holdings held 8,597 shares of Quest Diagnostics worth $1.82M as of Q2 2026.
- Crossmark Global Holdings bought 93 Quest Diagnostics shares in Q2 2026, an estimated $18.3K.
- Quest Diagnostics made up 0.02% of Crossmark Global Holdings's portfolio in Q2 2026, its #478 holding.
- Crossmark Global Holdings first reported a position in Quest Diagnostics in Q3 2016 and has held it in 37 quarters since.
- Crossmark Global Holdings's Quest Diagnostics position peaked at $20.1M in Q4 2021.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.